NEW YORK (360Dx) – Abbott said on Thursday that the US Food and Drug Administration has cleared the company's Afinion HbA1c Dx assay to help diagnose diabetes mellitus and assess a patient's risk of developing the disease.

The rapid point-of-care assay was cleared to run on Abbott's Afinion AS100 Analyzer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.